Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Delta Air Lines, Inc. DAL reported better-than-expected fourth-quarter results and issued 2025 guidance. Delta reported ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

IGM Biosciences (NASDAQ: IGMS), a biotechnology company, has seen a sharp 67% drop in its stock value on Friday following the suspension of two of its treatments ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.